Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Condition:   Multiple Myeloma Intervention:   Drug: Pomalidomide + Cyclophosphamide + Dexamethasone Sponsor:   Maimónides Biomedical Research Institute of Córdoba Terminated

Source: ClinicalTrials.gov - January 28, 2020 Category: Research Source Type: clinical trials